- Home
- MAMO vs PROK Comparison
MAMO vs PROK Comparison
Compare MAMO & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAMO
- PROK
- Stock Information
- Founded
- MAMO 2008
- PROK 2015
- Country
- MAMO United States
- PROK United States
- Employees
- MAMO N/A
- PROK N/A
- Industry
- MAMO
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MAMO
- PROK Health Care
- Exchange
- MAMO NYSE
- PROK Nasdaq
- Market Cap
- MAMO 98.1M
- PROK 94.9M
- IPO Year
- MAMO 2024
- PROK N/A
- Fundamental
- Price
- MAMO $2.28
- PROK $0.70
- Analyst Decision
- MAMO
- PROK Buy
- Analyst Count
- MAMO 0
- PROK 4
- Target Price
- MAMO N/A
- PROK $5.00
- AVG Volume (30 Days)
- MAMO 15.1K
- PROK 1.2M
- Earning Date
- MAMO 05-13-2025
- PROK 05-16-2025
- Dividend Yield
- MAMO N/A
- PROK N/A
- EPS Growth
- MAMO N/A
- PROK N/A
- EPS
- MAMO 0.08
- PROK N/A
- Revenue
- MAMO $111,209,142.00
- PROK $76,000.00
- Revenue This Year
- MAMO N/A
- PROK N/A
- Revenue Next Year
- MAMO N/A
- PROK N/A
- P/E Ratio
- MAMO $29.64
- PROK N/A
- Revenue Growth
- MAMO N/A
- PROK N/A
- 52 Week Low
- MAMO $2.16
- PROK $0.46
- 52 Week High
- MAMO $4.66
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- MAMO N/A
- PROK 41.42
- Support Level
- MAMO N/A
- PROK $0.94
- Resistance Level
- MAMO N/A
- PROK $0.77
- Average True Range (ATR)
- MAMO 0.00
- PROK 0.12
- MACD
- MAMO 0.00
- PROK -0.01
- Stochastic Oscillator
- MAMO 0.00
- PROK 17.63
About MAMO MASSIMO GROUP
Massimo Group is engaged in the mid-tier band the (Mid-Tier Band) of the Powersports Vehicles and Boats Industry. It manufacture, import and distribute a diversified portfolio of products divided into two main lines: a motor sports brand consisting of utility terrain vehicles (UTVs), all-terrain vehicles (ATVs), motorcycles, scooters, golf carts, and a juvenile line from go karts to balance bikes; and a motor boat line consisting of pontoon and tritoon boats (Pontoon Boats).
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.